Sigma-1R Protects Retinal Ganglion Cells in Optic Nerve Crush Model for Glaucoma.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
02 08 2021
02 08 2021
Historique:
entrez:
18
8
2021
pubmed:
19
8
2021
medline:
28
9
2021
Statut:
ppublish
Résumé
The purpose of this study was to determine the effects of the Sigma-1R (σ-1r) on retinal ganglion cell (RGC) survival following optic nerve crush (ONC) and the signaling mechanism involved in the σ-1r protection. The overall strategy was to induce injury by ONC and mitigate RGC death by increasing σ-1r expression and/or activate σ-1r activity in σ-1r K/O mice and wild type (WT) mice. AAV2-σ-1r vector was used to increase σ-1r expression and σ-1r agonist used to activate the σ-1r and RGCs were counted. Immunohistochemical and Western blot analysis determined phosphorylated (p)-c-Jun, c-Jun, and Caspase-3. Pattern electroretinography (PERG) determined RGC activity. RGC counts and function were similar in pentazocine-treated WT mice when compared to untreated mice and in WT mice when compared with σ-1r K/O mice. Pentazocine-induced effects and the effects of σ-1r K/O were only observable after ONC. ONC resulted in decreased RGC counts and activity in both WT and σ-1r K/O mice, with σ-1r K/O mice experiencing significant decreases compared with WT mice. The σ-1r transgenic expression resulted in increased RGC counts and activity following ONC. In WT mice, treatment with σ-1r agonist pentazocine resulted in increased RGC counts and increased activity when compared with untreated WT mice. There were time-dependent increases in c-jun, p-c-jun, and caspase-3 expression in ONC mice that were mitigated with pentazocine-treatment. These findings suggest that the apoptotic pathway is involved in RGC losses seen in an ONC model. The σ-1r offers neuroprotection, as activation and/or transgenic expression of σ-1r attenuated the apoptotic pathway and restored RGCs number and function following ONC.
Identifiants
pubmed: 34406331
pii: 2776609
doi: 10.1167/iovs.62.10.17
pmc: PMC8375012
doi:
Substances chimiques
Receptors, sigma
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Références
Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2412-21
pubmed: 10937548
Invest Ophthalmol Vis Sci. 2015 Sep 1;56(10):6144-61
pubmed: 26397462
Neurosci Lett. 2011 Nov 14;505(2):76-81
pubmed: 21996423
EMBO J. 2006 Mar 8;25(5):1058-69
pubmed: 16511568
Br J Ophthalmol. 2007 Oct;91(10):1382-4
pubmed: 17522150
J Biomed Sci. 2017 Sep 16;24(1):74
pubmed: 28917260
J Neurosci Res. 2006 Apr;83(5):907-18
pubmed: 16477618
Neurobiol Dis. 2012 May;46(2):393-401
pubmed: 22353563
Adv Exp Med Biol. 2020;1131:699-718
pubmed: 31646531
Exp Eye Res. 2013 Feb;107:21-31
pubmed: 23183135
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4154-61
pubmed: 18469181
Exp Eye Res. 2005 May;80(5):663-70
pubmed: 15862173
Trends Cell Biol. 2009 Feb;19(2):81-8
pubmed: 19144519
J Comp Neurol. 2014 Apr 15;522(6):1411-43
pubmed: 24318667
Exp Eye Res. 2014 Nov;128:156-69
pubmed: 25305575
Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2755-2764
pubmed: 28549090
Neurosci Lett. 2019 Oct 15;711:134387
pubmed: 31330223
Mol Neurobiol. 2017 Jan;54(1):72-86
pubmed: 26732591
Free Radic Biol Med. 2015 Sep;86:25-36
pubmed: 25920363
Sci Rep. 2015 Jun 02;5:10689
pubmed: 26033680
PLoS One. 2013 Nov 12;8(11):e79183
pubmed: 24265756
Prog Retin Eye Res. 2018 Nov;67:130-149
pubmed: 30075336
Invest Ophthalmol Vis Sci. 1999 Apr;40(5):1004-8
pubmed: 10102300
Mol Neurodegener. 2016 Apr 21;11:30
pubmed: 27098079
PLoS One. 2017 Sep 12;12(9):e0184421
pubmed: 28898265
Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7749-60
pubmed: 21862648
Ophthalmic Epidemiol. 2006 Aug;13(4):283-9
pubmed: 16877288
Cell Mol Neurobiol. 2016 May;36(4):531-40
pubmed: 26119305
Mol Vis. 2011 Apr 26;17:1034-43
pubmed: 21541278
Nature. 2005 Sep 8;437(7056):281-5
pubmed: 16007074
J Neurosci Res. 1993 Feb 1;34(2):250-5
pubmed: 8450568
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1052-8
pubmed: 19737887
Mol Vis. 2012;18:2860-70
pubmed: 23233788
Neuroreport. 2005 Aug 1;16(11):1223-6
pubmed: 16012353
Cell. 2007 Nov 2;131(3):596-610
pubmed: 17981125
Pharmacol Ther. 2009 Nov;124(2):195-206
pubmed: 19619582
Mol Vis. 2011 Apr 06;17:864-75
pubmed: 21527996